Thalidomide-O-COOH

Background Introduction

Thalidomide-O-COOH is a functionalized derivative of thalidomide, featuring a carboxylic acid group for straightforward conjugation. As a cereblon (CRBN) E3 ligase ligand, this molecule is widely used in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling targeted protein degradation applications in biomedical research and drug discovery.

Mechanism

Thalidomide-O-COOH binds selectively to the CRBN protein, a substrate receptor component of the CRL4 E3 ubiquitin ligase complex. When used as part of a PROTAC molecule, it acts as an E3 ligase recruiter. The carboxylic acid moiety allows for easy linker attachment, facilitating the covalent connection to a target protein ligand. Upon successful linking, the resulting bifunctional PROTAC molecule brings the E3 ligase and the target protein into close proximity, enabling ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-O-COOH is a key building block in the synthesis of CRBN-based PROTACs, allowing researchers to design molecules for selective protein degradation of disease-relevant targets. It is ideal for chemical biology studies, mechanism-of-action investigations, and early-stage drug development in oncology, neurodegenerative diseases, and immune disorders. Additionally, it is utilized in developing next-generation targeted therapies with improved selectivity and reduced off-target effects.

• Carboxylic acid functionality enables versatile coupling with amine-containing partners for PROTAC assembly.
• Specifically designed for efficient and reliable CRBN E3 ligase recruitment in targeted protein degradation applications.

Thalidomide-O-COOH serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by bridging the E3 ligase and target protein. The following provides a detailed description of this molecule's linker, ligand, and selection of target protein ligands.

Linker: The linker in Thalidomide-O-COOH is typically a short, flexible chain that allows optimal spatial orientation between the E3 ligase and the target protein. Its flexibility enhances the molecule's adaptability, while its cleavability can be tailored to release the ligand under specific cellular conditions.

Ligand: The ligand component is derived from thalidomide, known for its potent binding affinity to the cereblon E3 ligase. This structural characteristic ensures efficient recruitment of the E3 ligase, promoting ubiquitination and subsequent degradation of the target protein.

Reactive Site: The reactive site in Thalidomide-O-COOH is the carboxylic acid group, which readily forms amide bonds with amine groups on target protein ligands. Recommended reaction types include amide coupling reactions, such as those facilitated by EDC or HATU, ensuring stable conjugation.

Recommended Target Protein Ligand: A suitable warhead for this molecule is a small molecule with a reactive amine group, which can form a stable amide linkage with the carboxylic acid of Thalidomide-O-COOH. This configuration enhances the specificity and efficacy of the PROTAC, making it ideal for applications in studying protein function and validating therapeutic targets in cellular models.